Risk of thrombosis in adults with primary immune thrombocytopenia treated with eltrombopag versus romiplostim: a target trial emulation in the French Adult Immune Thrombocytopenia (FAITH) Cohort - Pub
3 hours ago
- #TPO-RAs comparison
- #immune thrombocytopenia
- #thrombosis risk
- The study compared thrombosis risk between eltrombopag and romiplostim in adults with primary immune thrombocytopenia (ITP).
- Using French healthcare data from 2011-2022, it involved 2,761 patients on eltrombopag and 949 on romiplostim, with the latter group being older and having more thrombosis risk factors.
- The 1-year weighted cumulative incidence of thrombosis was higher with eltrombopag (5.1%) than romiplostim (1.9%), with an adjusted hazard ratio of 1.93 favoring romiplostim.
- Significant risk differences emerged after 6 months of treatment and were most pronounced in patients aged 75 years and older.
- Both venous and arterial thrombosis risks were similarly elevated with eltrombopag compared to romiplostim.